International Research Journal of Education and Technology
Peer Reviewed Journal
ISSN 2581-7795

Association between Albumin and transferrin in patients with End-Stage Liver Disease.

Ms. Anuradha, Research scholar, Malwanchal University, Indore

Dr.Jaya Jain ,Research Supervisor, Malwanchal University, Indore

Introduction

It was assumed that having an excess of iron made people with liver illness more likely to die. It has been shown that patients with acute-on-chronic liver failure and decompensated cirrhosis benefit from having their transferrin and transferrin saturation levels checked as survival indicators. Transferrin is thus essential to the treatment of these people. Patients with cirrhosis who have low transferrin levels have decreased synthetic function. A risk factor for the development of the disease and death in cirrhosis is inflammation, which may be indicated by high ferritin and low transferrin levels. The metabolism of iron may also be indirectly impacted by alcohol and other metabolic variables. It is thus yet unclear whether altered iron metabolism is a cause or a result of the numerous causes of severe liver disease. To determine how inflammation and hepatic function affected serum iron parameters, blood ferritin, transferrin, and transferrin saturation levels were associated with C-reactive protein and albumin levels. This made it possible to examine the relationship between liver function and inflammation and iron levels in the blood. The prognostic significance of each of these measures was validated by a survival study performed on a large, unselected cohort of cirrhotic patients.

Methodology

We were able to gather data of a clinical, social, and biological character by analysing patient records from the past. From an initial cohort of 210 consecutive patients with liver cirrhosis who presented at the Index Medical College in Indore, only 200 persons were included in the final analysis because of the removal of 10 patients who had hepatocellular carcinoma or another malignancy at the time of diagnosis. This reduced the number of people that took part in the research to 200. Clinical, biochemical, and imaging results all converged to confirm the presence of cirrhosis. The ethics board of Malwanchal University has granted its OK for us to go on with this research. Outpatient care accounted for the bulk of the 118 patients seen. Eighty-two people were rushed to the hospital, and 30 of them were admitted to critical care units. The cohort was established from the baseline serum iron parameters measurement taken at the start of the experiment. Death, liver transplantation, or the end of the study's final follow-up were the three possible outcomes. The prognosis was thus established by utilising the 1-year and 5-year transplant-free survival rates, with right-censoring for individuals who had had liver transplantation or who could not be located for further study.

Results

Clinical and biochemical parameters were retrospectively analysed in a cohort of 200 cirrhosis patients to establish whether or not transferrin is a predictor of survival in unselected persons with cirrhosis. The purpose of this analysis was to

establish whether or not transferrin is a reliable predictor of mortality. Twenty percent of patients died during the median three-year follow-up period, and 32 percent had a liver transplant. The results of the ROC analysis indicated that a transferrin level of 180 mg/dL was the optimum threshold for predicting a transplant-free survival rate of 3 months. Estimates for transplant-free survival at 1 and 3 years were considerably lower in the group of patients with transferrin 180 mg/dL than in the group of patients with transferrin 180 mg/dL (89% vs 32.1%;). Patients with transferrin levels lower than 180 mg/dL had an increased risk of being male and having cirrhosis caused by either alcoholic liver disease or nonalcoholic fatty liver disease, as determined by the transferrin-based categorization system. It was shown that patients with low transferrin levels had a higher MELD-Na score, a higher white cell count, and a higher CRP level than those with normal transferrin levels. Next, we separated people into groups based on the underlying condition they were experiencing to determine whether that affected transferrin's predictive abilities. There was no statistically significant difference in transplant-free survival rates between those with ALD/NAFLD and those with other etiologies of cirrhosis, according to these findings (the log-rank P value was 0.11, and the significance level was set at 0.05). Higher transferrin levels were associated with longer survival in patients with cirrhosis not due to ALD or NAFLD (hazard ratio [HR], 0.849; 95% confidence interval [CI], 0.843-0.892; P 0.001 for both). Transferrin was significantly associated with transplant-free survival in separate subgroup analyses for patients with ALD and NAFLD (ALD—HR, 0.544; 95% CI, 0.417-0.899; P = 0.02; NAFLD—HR, 0.546; 95% CI, 0.440-0.881; P 0.001); however, this association was lost for both subgroups when MELD or MELD-Na was added to a multivariate mode. Impaired hepatic function, inflammation, alcohol use, and the metabolic syndrome all contribute to the low transferrin levels often seen in cirrhotic

individuals. Our research shows that transferrin is correlated with CRP, but it also acts as a survival signal in its own right. When looked at independently of albumin, transferrin is not a good indication of long-term health following a transplant.

Discussion

The amount of transferrin was shown to be a more reliable predictor of transplant-free survival than the MELD-Na score when it came to individuals who did not meet the prior selection criteria for cirrhosis. When the transferrin level is less than 180 mg/dL, the prognosis is significantly improved regardless of the cause of the cirrhosis or the severity of the condition. The prognostic role of transferrin has been shown to have no connection to inflammation after further in-depth survival modelling was performed on this enormous sample. Albumin seems to be a more reliable predictor of survival than transferrin in patients diagnosed with ALD and NAFLD. As evidenced by the independent connection between transferrin and survival in individuals without fatty liver disease, alcohol and metabolic variables both place an extra load on iron metabolism and alter the predictive potential of blood iron measurements in patients with cirrhosis.

Reference

1) Bai, C. H., Wu, M. S., Owaga, E., Cheng, S. Y., Pan, W. H., and Chang, J. S. (2014). Relationship between hemoglobin levels and risk for suspected

non-alcoholic fatty liver in Taiwanese adults. Chin. J. Physiol. 57, 286–294. doi: 10.4077/CJP.2014.BAD280

2) Chapoutot, C., Esslimani, M., Joomaye, Z., Ramos, J., Perney, P., Laurent, C., et al. (2000). Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 46, 711–714. doi: 10.1136/gut.46.5.711

3) Chen, J. X., and Chloupkova, M. (2009). Abnormal iron uptake and liver cancer. Cancer Biol. Ther. 8, 1699–1708. doi: 10.4161/cbt.8.18.9146

4) Facciorusso, A., Del Prete, V., Antonino, M., Neve, V., Crucinio, N., Di Leo, A., et al. (2014). Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J. Gastroenterol. Hepatol. 29, 1905–1910. doi: 10.1111/jgh.12618

5) Fargion, S., Piperno, A., Fracanzani, A. L., Cappellini, M. D., Romano, R., and Fiorelli, G. (1991). Iron in the pathogenesis of -Carcinoma. Italian J. Gastroenterol. 23, 584–588.

6) Fernandez-Ruiz, M., Guerra-Vales, J. M., Vila-Santos, J., and Colina-Ruizdelgado, F. (2009). Prognostic prediction in patients with hepatocellular carcinoma not amenable to locoregional treatment. Med. Clin. 133, 581–585. doi: 10.1186/1471-230X-10-146

7) Fujita, N., and Takei, Y. (2007). Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J. Gastroenterol. 42, 923–926. doi: 10.1007/s00535-007-2110-4

8) Furutani, T., Hino, K., Okuda, M., Gondo, T., Nishina, S., Kitase, A., et al. (2006). Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130, 2087–2098. doi: 10.1053/j.gastro.2006.02.060

9) Guo, C. H., Chen, P. C., Lin, K. P., Shih, M. Y., and Ko, W. S. (2012). Trace metal imbalance associated with oxidative stress and inflammatory status in anti-hepatitis C virus antibody positive subjects. Environ. Toxicol. Pharmacol. 33, 288–296. doi: 10.1016/j.etap.2011.12.018

10) Guo, H., Wu, T., Lu, Q., Dong, J., Ren, Y. F., Nan, K. J., et al. (2017). Hepatocellular carcinoma in elderly: clinical characteristics, treatments and outcomes compared with younger adults. PLoS ONE 12:e0184160. doi: 10.1371/journal.pone.0184160

11) Hajiani, E., Masjedizadeh, R., Hashemi, J., Azmi, M., and Rajabi, T. (2005). Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med. J. 26, 974–977.

12) Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., et al. (2017). Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J. Clin. Transl. Hepatol. 5, 297–318. doi: 10.14218/JCTH.2016.00019

13) Hwang, S., Lee, Y. J., Kim, K. H., Ahn, C. S., Moon, D. B., Ha, T. Y., et al. (2015). The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J. Gastrointest. Surg. 19, 1281–1290. doi: 10.1007/s11605-015-2849-5